A team led by Reuben Harris, professor in the Department of Biochemistry, Molecular Biology, and Biophysics, and Douglas Yee, director of the Masonic Cancer Center, and professor in the Department of Medicine and Pharmacology, were recently awarded a P01 from NCI.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
